Sponsor: 
GlaxoSmithKline Australia
Administration route: 
Intramuscular injection, Subcutaneous injection
Vaccine group: 
Combination vaccines

Registered for use in people aged ≥9 months.

MMRV — measles-mumps-rubella-varicella combination vaccine

Lyophilised pellet in a monodose vial with a pre-filled diluent syringe.

Each 0.5 mL reconstituted dose contains:

  • ≥103.0 cell culture infectious dose 50% (CCID50) of live attenuated measles virus (Schwarz strain)
  • ≥104.4 CCID50 of live attenuated mumps virus (RIT 4385 strain, derived from the Jeryl Lynn strain)
  • ≥103.0 CCID50 of live attenuated rubella virus (Wistar RA 27/3 strain)
  • ≥103.3 plaque-forming units of live attenuated varicella-zoster virus (Oka strain)
  • lactose
  • neomycin
  • sorbitol
  • mannitol

For full details, refer to the product information and consumer medicine information sheets for Priorix-tetra vaccine available on the TGA website.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018

Definitions

MMRV
measles-mumps-rubella-varicella